Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 3/20 | 0.65 |
| ▸ | PLAU | P00749 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435605 | 0.95 | PLG (0.72) | PLGPLAUMEN1KMT2APOLB | |
| SCHEMBL6436937 | 0.87 | PLG (0.53) | PLGPLAUMEN1KMT2AF2 | |
| SCHEMBL6437758 | 0.84 | PLAU (0.55) | PLGPLAUMEN1KMT2AF2 | |
| SCHEMBL7396111 | 0.80 | PLG (0.74) | PLGPLAUMEN1KMT2APOLB | |
| Trifluoroacetic Acid SCHEMBL6434729 | 0.80 | PLAU (0.62) | PLGPLAUF2PLATTMPRSS6 | |
| Trifluoroacetic Acid SCHEMBL6434310 | 0.79 | PLAU (0.63) | PLGPLAUPLAT | |
| Trifluoroacetic Acid SCHEMBL6438578 | 0.79 | PLAU (0.63) | PLGPLAUF2PLATTMPRSS6 | |
| SCHEMBL6436460 | 0.77 | PLAU (0.71) | PLGPLAUMEN1KMT2APOLB | |
| Trifluoroacetic Acid SCHEMBL6437930 | 0.77 | PLAU (0.64) | PLGPLAUPLAT | |
| Trifluoroacetic Acid SCHEMBL6432939 | 0.77 | F2 (0.47) | PLGPLAUF2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLG 33/4885PLAU 119/4885MEN1 4591/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLG 33/4885PLAU 119/4885MEN1 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.